SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-24-005677
Filing Date
2024-04-25
Accepted
2024-04-25 07:00:43
Documents
19
Period of Report
2024-06-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A acrs-20240606xdef14a.htm   iXBRL DEF 14A 1332757
2 GRAPHIC acrs-20240606xdef14a_a001.jpg GRAPHIC 4507
3 GRAPHIC acrs-20240606xdef14a_a016.jpg GRAPHIC 52261
4 GRAPHIC acrs-20240606xdef14a_a017.jpg GRAPHIC 51709
5 GRAPHIC acrs-20240606xdef14a_bg001.jpg GRAPHIC 130652
6 GRAPHIC acrs-20240606xdef14a_bg002.jpg GRAPHIC 103669
  Complete submission text file 0001558370-24-005677.txt   3424842

Data Files

Seq Description Document Type Size
7 EX-101.SCH acrs-20240606.xsd EX-101.SCH 5804
8 EX-101.DEF acrs-20240606_def.xml EX-101.DEF 7011
9 EX-101.LAB acrs-20240606_lab.xml EX-101.LAB 13801
10 EX-101.PRE acrs-20240606_pre.xml EX-101.PRE 7069
22 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240606xdef14a_htm.xml XML 487199
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37581 | Film No.: 24872830
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)